A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction

Rhodes, Julia C.; Kahn, Rebecca; Bolcen, Shanna; Shang, Nong; Chung, Yunmi; Farley, Monica M.; Britton, Amber N.; Moore, Ashley E.; Thomas, Stepy; Nadle, Joelle; Amsden, Laura B.; Skarbinski, Jacek; VanWinden, Kristi R.; Barnes, Meghan; Engesser, Kerianne; Ferrieri, Patricia; Hansen, AmberJean P.; Harrison, Lee H.; Jeffrey, Laura; Nyholm, Jessica L.; O’Leary, Sean T.; Olson-Chen, Courtney; Rowlands, Jemma V.; Seopaul, Shannon A.; Thomas, Ann R.; Wrigley, Htet Htet N.; McGee, Lesley; Vishwanathan, Sundaram Ajay; Akhter, Fahmina; Alston, Bailey; Jia, Lily Tao; Li, Yikun; Patel, Palak Y.; Rivers, Joy; Southwell, Jessica E.; Tran, Theresa; Maniatis, Panagiotis; Schrag, Stephanie J.

A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction

Julia C. Rhodes (), Rebecca Kahn, Shanna Bolcen, Nong Shang, Yunmi Chung, Monica M. Farley, Amber N. Britton, Ashley E. Moore, Stepy Thomas, Joelle Nadle, Laura B. Amsden, Jacek Skarbinski, Kristi R. VanWinden, Meghan Barnes, Kerianne Engesser, Patricia Ferrieri, AmberJean P. Hansen, Lee H. Harrison, Laura Jeffrey, Jessica L. Nyholm, Sean T. O’Leary, Courtney Olson-Chen, Jemma V. Rowlands, Shannon A. Seopaul, Ann R. Thomas, Htet Htet N. Wrigley, Lesley McGee, Sundaram Ajay Vishwanathan, Fahmina Akhter, Bailey Alston, Lily Tao Jia, Yikun Li, Palak Y. Patel, Joy Rivers, Jessica E. Southwell, Theresa Tran, Panagiotis Maniatis and Stephanie J. Schrag ()
Additional contact information
Julia C. Rhodes: Centers for Disease Control and Prevention
Rebecca Kahn: Centers for Disease Control and Prevention
Shanna Bolcen: Centers for Disease Control and Prevention
Nong Shang: Centers for Disease Control and Prevention
Yunmi Chung: Centers for Disease Control and Prevention
Monica M. Farley: Emory University School of Medicine
Amber N. Britton: Emory University School of Medicine
Ashley E. Moore: Georgia Department of Public Health
Stepy Thomas: Emory University School of Medicine
Joelle Nadle: California Emerging Infections Program
Laura B. Amsden: Kaiser Permanente Northern California
Jacek Skarbinski: Kaiser Permanente Northern California
Kristi R. VanWinden: San Leandro
Meghan Barnes: Colorado Department of Public Health and Environment
Kerianne Engesser: New York State Department of Health
Patricia Ferrieri: University of Minnesota Medical School
AmberJean P. Hansen: Connecticut Emerging Infections Program
Lee H. Harrison: Johns Hopkins Bloomberg School of Public Health
Laura Jeffrey: Johns Hopkins Bloomberg School of Public Health
Jessica L. Nyholm: University of Minnesota Medical School
Sean T. O’Leary: University of Colorado School of Medicine
Courtney Olson-Chen: University of Rochester Medical Center
Jemma V. Rowlands: New York State Department of Health
Shannon A. Seopaul: Johns Hopkins Bloomberg School of Public Health
Ann R. Thomas: Oregon Health Authority
Htet Htet N. Wrigley: Connecticut Department of Public Health
Lesley McGee: Centers for Disease Control and Prevention
Sundaram Ajay Vishwanathan: Centers for Disease Control and Prevention
Fahmina Akhter: Centers for Disease Control and Prevention
Bailey Alston: Seneca Federal Health
Lily Tao Jia: Centers for Disease Control and Prevention
Yikun Li: Inc
Palak Y. Patel: Centers for Disease Control and Prevention
Joy Rivers: Centers for Disease Control and Prevention
Jessica E. Southwell: Inc
Theresa Tran: Centers for Disease Control and Prevention
Panagiotis Maniatis: Centers for Disease Control and Prevention
Stephanie J. Schrag: Centers for Disease Control and Prevention

Nature Communications, 2025, vol. 16, issue 1, 1-16

Abstract: Abstract Maternal vaccines to prevent infant Group B Streptococcus (GBS) disease have progressed through phase II development and may be licensed based on immunologic endpoints, which have yet to be approved by regulatory authorities. Here we present a multistate case control study to characterize the relationship between serotype-specific anti-capsular polysaccharide (CPS) immunoglobulin G concentrations near birth and infant GBS disease risk reduction. Antibody concentration distributions are significantly lower for cases (n = 643) than controls (n = 2801) and serologic thresholds varied by serotype and age at onset, with 80% serotype-specific protective thresholds ranging from 0.52 to 2.49 mcg/mL for early-onset disease (EOD;

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-64324-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-64324-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-64324-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().